• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 4th July 2017

OHE at ISPOR Boston 2017: Presentations and Posters

A selection of the posters and presentations delivered by OHE at the ISPOR 22nd Annual International Meeting in Boston, May 2017, are available below. Adrian Towse participated in an invited issues panel, alongside: Peter Neumann (Tufts Medical Center) (Moderator), Lou…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

A selection of the posters and presentations delivered by OHE at the ISPOR 22nd Annual International Meeting in Boston, May 2017, are available below.

Adrian Towse participated in an invited issues panel, alongside: Peter Neumann (Tufts Medical Center) (Moderator), Lou Garrison (University of Washington and OHE Senior Visiting Fellow), Eleanor Perfetto (National Health Council, US) and Edmund Pezalla (Enlightenment BioConsult), that looked at: ISPOR’s special task force report on us value assessment frameworks: what does it say and is it helpful? The white paper’s key points and recommendations were presented, and its contributions and limitations discussed from the perspective of three key stakeholder groups: patients, payers, and the non-US audience. Adrian gave the non-US perspective.

ISPOR Special Task Force on US Value Frameworks: A Non-US Perspective from Office of Health Economics

Nancy Devlin, along with co-panellists Shelby Reed, F. Reed Johnson and Sachin Kamal-Bahl discussed: Moving Beyond the QALY in Patient-Centered Value Frameworks: But, in what direction? The panel explored different perspectives on the way that patients’ preferences and views could best be incorporated into value frameworks. Nancy argued that there is a case for systematically considering evidence patient preferences as part of HTA processes. However, ultimately HTA decisions involve weighing up both benefits to patients affected by the technology and benefits foregone to other patients so there remains an important role for societal preferences.

Moving Beyond the QALY in Patient-Centered Value Frameworks: But, in What Direction? from Office of Health Economics
 
Adrian Towse participated in an issues panel entitled: Developing and paying for gene therapies: can we resolve the conflicts? Co-panelists were Bill Dreitlein (ICER) (moderator), John Watkins (Premera Blue Cross) and Clark Paramore (BlueBird Bio). The panel discussed the tension between manufacturers of gene therapies seeking compensation for their innovation at high prices, payers struggling with affordability, and technology assessment organisations wrestling with how to measure value. Adrian gave a European perspective.

Developing and Paying for Gene Therapies: Can We Resolve the Conflicts? A European Perspective from Office of Health Economics
 
Adrian Towse also moderated an issues panel on: Perspectives on the relationship between cost effectiveness and affordability. Adrian introduced the topic, highlighting relevant papers and questioning what we really mean by affordability in various contexts. Panellists Mark Sculpher (University of York), Patricia Danzon (University of Pennsylvania) and Steve Pearson (ICER) discussed cost-effectiveness analysis, budget thresholds, and the potential effect of budget impact on the cost-effectiveness threshold.

Perspectives on the Relationship Between Cost Effectiveness and Affordability from Office of Health Economics
 

Paula Lorgelly presented three posters:

  • Comparing HTA outcomes for centrally authorised medicinal products in Great Britain 2011-2015. Authors: Maignen, F., Zamora, B., O’Neill, P., Garau, M., Lorgelly, P.
    Most new substances are approved in the European Union via the centralised procedure (coordinated by the European Medicines Agency); many health care systems in Europe then evaluate new technologies according to their effectiveness and cost effectiveness. This poster presents a comparison of outcomes of HTA evaluations for centrally authorised products in Great Britain.
  • Adjusting for differential item functioning in the EQ-5D-5L using externally-collected vignettes. Authors: Lorgelly, P., Knott, R. (Monash University).
    There is concern that responses to questions on subjective scales will be inaccurate if certain groups of people systematically differ in their interpretation and use of the response categories – known as differential item functioning (DIF). It is possible to correct for DIF by using vignette responses collected externally to the main dataset of interest. This poster shows how this approach can be applied to the EQ-5D-5L to obtain QALY measures that are comparable across different population groups.
  • Comparing cancer-specific preference-based outcome measures: the same but different. Authors: Lorgelly, P., Norman, R. (Curtin University).
    Disease-specific outcome measures for use in economic evaluations are growing in popularity. Within cancer there are now two preference-based measures, the EORTC-8D and the QLU-C10D. This poster presents research that compares these two measures.

Comparing HTA Outcomes for Centrally Authorized Medicinal Products in Great Britain 2011-2015 from Office of Health Economics
 

Adjusting for Differential Item Functioning in the EQ-5D-5L Using Externally-Collected Vignettes from Office of Health Economics
 

Comparing Cancer-Specific Preference-Based Outcome Measures: The Same but Different from Office of Health Economics
 

The OHE team were also actively involved in a number of ISPOR events held in Boston alongside the conference, including:

  • Nancy Devlin was an instructor on an ISPOR short course on MCDA, along with Maarten Ijzerman and Kevin Marsh
  • Adrian Towse was an instructor on an ISPOR short course on Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products, along with Lou Garrison and Josh Carlson
  • Nancy Devlin participated in Board of Directors meeting, and chaired a meeting of the Management and Advisory Board of ISPOR journals
  • Nancy Devlin participated in a Patient Representatives Roundtable Forum.

For more information on any of the above please contact the relevant author via our meet the team webpage.

  • EQ-5D and PROMs
  • NICE

Related News

  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!